Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India

Indian Journal of Endocrinology and Metabolism

Volumn 18, Issue 1, 2014, Pages 77-82

  Kaur, Parjeet ^a   Mishra, Sunil ^a   Mithal, Ambrish ^a   Saxena, Meenal ^a   Makkar, Anshu ^a   Sharma, Pooja ^a  

^a MEDANTA THE MEDICITY   (India)

Author keywords

GLP 1 receptor agonists; India; obesity; type 2 diabetes

Indexed keywords

EID: 84995376436     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.126572     Document Type: Article

References (23)

1. Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, et al. ICMR-INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia 2011;54:3022-7.
2. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6.
3. Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70:90-7.
4. Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am 2005;34:155-97.
5. Gonzalez C, Beruto V, Keller G, Santoro S, Di Girolamo G. Investigational treatments for Type 2 diabetes mellitus: Exenatide and liraglutide. Expert Opin Investig Drugs 2006;15:887-95.
6. Wajcberg E, Amarah A. Liraglutide in the management of type 2 diabetes. Drug Des Devel Ther 2010;4:279-90.
7. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35:S11-63.
8. Ponzani P, Corsi A. Incretin-based therapies in clinical practice: From efficacy to effectiveness. Focus on liraglutide. Minerva Endocrinol 2012;37:1-8.
9. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010;26:1013-22.
10. Zenari L. Efficacy and tolerability of liraglutide in combination with other antidiabetic drugs in type 2 diabetes. Acta Biomed 2011;82:251-3.
11. Raskin P, Mora PF. Glycaemic control with liraglutide: The phase 3 trial programme. Int J Clin Pract Suppl 2010:21-7.
12. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
13. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
14. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
15. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009;52:2046-55.
16. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
17. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
18. Victoza®. (Package insert). Princeton, NJ: Novo Nordisk Inc. January 2010.
19. Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: A 16-week, randomized, double-blind, active control trial (FNx01). Diabetes Obes Metab 2011;13:81-8.
20. Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010;12:341-7.
21. Seino Y, Rasmussen MF, Nishida T, Kaku K. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs. sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial. J Diabetes Invest 2011;2:280-6.
22. Bawa T, Dhingra V, Malhotra N, Wasir JS, Mithal A. Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus. Indian J Endocrinol Metab 2013;17:91-4.
23. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.